• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

作者信息

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer M R, Ritchie E, Silver R T, Kessler C, Winton E, Finazzi M C, Rambaldi A, Vannucchi A M, Leibowitz D, Rondelli D, Arcasoy M O, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama M E, Weinberg R S, Rampal R, Goldberg J D, Mesa R, Dueck A C, Hoffman R

机构信息

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Mayo Clinic, Scottsdale, AZ, USA.

出版信息

Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30.

DOI:10.1038/s41375-019-0524-7
PMID:31363161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6884668/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d86/6884668/3203c62c472c/nihms-1529755-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d86/6884668/3203c62c472c/nihms-1529755-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d86/6884668/3203c62c472c/nihms-1529755-f0001.jpg

相似文献

1
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.对曾有内脏静脉血栓形成的真性红细胞增多症和原发性血小板增多症患者进行聚乙二醇化干扰素α-2a治疗的前瞻性评估。
Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30.
2
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.聚乙二醇化干扰素α-2a治疗原发性血小板增多症或真性红细胞增多症患者：一项开放标签2期试验的事后分析，中位随访83个月
Lancet Haematol. 2017 Apr;4(4):e165-e175. doi: 10.1016/S2352-3026(17)30030-3. Epub 2017 Mar 11.
3
Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.聚乙二醇干扰素α-2b治疗慢性骨髓增殖性疾病
Ter Arkh. 2018 Aug 17;90(7):23-29. doi: 10.26442/terarkh201890723-29.
4
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.聚乙二醇干扰素 α-2a 可使晚期原发性血小板增多症和红细胞增多症患者获得较高的血液学和分子学缓解率。
J Clin Oncol. 2009 Nov 10;27(32):5418-24. doi: 10.1200/JCO.2009.23.6075. Epub 2009 Oct 13.
5
Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.聚乙二醇化干扰素α-2a在非临床试验治疗的骨髓增殖性肿瘤患者中临床有效且耐受性良好。
Leuk Res. 2017 Mar;54:73-77. doi: 10.1016/j.leukres.2017.01.006. Epub 2017 Jan 5.
6
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.聚乙二醇干扰素在年轻的真性红细胞增多症和原发性血小板增多症患者中的应用。
Pediatr Blood Cancer. 2021 Mar;68(3):e28888. doi: 10.1002/pbc.28888. Epub 2020 Dec 31.
7
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.聚乙二醇干扰素 α-2a 治疗对羟基脲耐药或不耐受的真性红细胞增多症或原发性血小板增多症。
Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.
8
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.聚乙二醇化干扰素α-2a用于妊娠期原发性血小板增多症：结局与安全性。病例系列报道
Haematologica. 2016 May;101(5):e182-4. doi: 10.3324/haematol.2015.139691. Epub 2016 Jan 27.
9
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.聚乙二醇干扰素α-2b用于真性红细胞增多症患者的治疗。
Drugs Today (Barc). 2020 Mar;56(3):195-202. doi: 10.1358/dot.2020.56.3.3107706.
10
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.聚乙二醇化干扰素α-2a与羟基脲治疗真性红细胞增多症和原发性血小板增多症：细胞和分子反应的差异
Leukemia. 2018 Aug;32(8):1830-1833. doi: 10.1038/s41375-018-0080-6. Epub 2018 Feb 28.

引用本文的文献

1
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs.骨髓增殖性肿瘤中的内脏静脉血栓形成：治疗考量与未满足的需求
Cancers (Basel). 2022 Dec 20;15(1):11. doi: 10.3390/cancers15010011.
2
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.高危原发性血小板增多症和真性红细胞增多症患者接受羟基脲或聚乙二醇干扰素α-2a 治疗后的症状负担和生活质量：MPN-RC 111 和 112 试验的事后分析。
Lancet Haematol. 2022 Jan;9(1):e38-e48. doi: 10.1016/S2352-3026(21)00343-4.
3
Running interferon interference in treating PV/ET: meeting unmet needs.
干扰素干扰治疗 PV/ET：满足未满足的需求。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):463-468. doi: 10.1182/hematology.2021000280.
4
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.真性红细胞增多症：历史的忽视、诊断的细节和治疗的观点。
Leukemia. 2021 Dec;35(12):3339-3351. doi: 10.1038/s41375-021-01401-3. Epub 2021 Sep 3.
5
Recent advances in prognostication and treatment of polycythemia vera.真性红细胞增多症预后及治疗的最新进展
Fac Rev. 2021 Mar 12;10:29. doi: 10.12703/r/10-29. eCollection 2021.
6
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.临床视角下骨髓增殖性肿瘤中血栓形成的起源。
Blood. 2021 Mar 4;137(9):1145-1153. doi: 10.1182/blood.2020008043.
7
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.使用idasanutlin治疗的真性红细胞增多症患者中TP53突变克隆的短暂扩增。
Blood Adv. 2020 Nov 24;4(22):5735-5744. doi: 10.1182/bloodadvances.2020002379.
8
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.新型和联合疗法治疗真性红细胞增多症和原发性血小板增多症：新时代的曙光。
Expert Rev Hematol. 2020 Nov;13(11):1189-1199. doi: 10.1080/17474086.2020.1839887. Epub 2020 Nov 1.
9
Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.干扰素 α 治疗原发性血小板增多症和真性红细胞增多症的系统评价和荟萃分析。
Leukemia. 2021 Jun;35(6):1643-1660. doi: 10.1038/s41375-020-01020-4. Epub 2020 Sep 1.
10
Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症中的血栓形成、炎症和低氧诱导因子调节基因与血栓形成风险
Blood Adv. 2020 Mar 24;4(6):1115-1130. doi: 10.1182/bloodadvances.2019001379.